Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

3.9%

13 terminated/withdrawn out of 330 trials

Success Rate

94.5%

+7.9% vs industry average

Late-Stage Pipeline

31%

101 trials in Phase 3/4

Results Transparency

20%

44 of 223 completed trials have results

Key Signals

18 recruiting44 with results11 terminated

Enrollment Performance

Analytics

Phase 3

77(28.6%)

N/A

75(27.9%)

Phase 1

46(17.1%)

Phase 2

42(15.6%)

Phase 4

24(8.9%)

Early Phase 1

5(1.9%)

269Total

Phase 3(77)

N/A(75)

Phase 1(46)

Phase 2(42)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (330)

Showing 20 of 330 trials

NCT05600062Not ApplicableCompleted

Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)

Role: collaborator

NCT07339982Not ApplicableCompleted

Supermarket Labelling and Taxation Study

Role: collaborator

NCT06560853Not ApplicableActive Not Recruiting

Evaluation of a Comprehensive School Health Programme in Zambia

Role: collaborator

NCT06860334Phase 2Recruiting

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

Role: collaborator

NCT05653063Active Not Recruiting

ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

Role: collaborator

NCT03684278Phase 2Recruiting

Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)

Role: collaborator

NCT06624787Not ApplicableRecruiting

Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care

Role: collaborator

NCT04844775Phase 1Completed

A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Role: collaborator

NCT06061822Not ApplicableRecruiting

Artificial Intelligence Delivered Cardiac Magnetic Resonance - Prospective Validation

Role: collaborator

NCT04923958Not ApplicableRecruiting

Rapid Research in Diagnostics Development for TB Network

Role: collaborator

NCT04316494Phase 4Terminated

Hydroxychloroquine in ANCA Vasculitis Evaluation

Role: collaborator

NCT03640377Phase 2Completed

Praziquantel in Children Under Age 4

Role: collaborator

NCT07103681Recruiting

White Matter Distortion and Dementia Biomarkers in Normal Pressure Hydrocephalus (NPH)

Role: collaborator

NCT06678022Not ApplicableRecruiting

Use of Unmanned Air Vehicles (Medical Drones) to Overcome Geographical Barriers to Delivery of Anti-Retroviral Therapy and Biological Samples

Role: collaborator

NCT06478277Recruiting

UK CARDIOvascular Immune-Mediated Inflammatory Diseases (CARDIO-IMID) Registry Study

Role: collaborator

NCT04349826Phase 4Completed

The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)

Role: collaborator

NCT04241276Phase 2Active Not Recruiting

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

Role: collaborator

NCT07300683Phase 1Recruiting

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

Role: collaborator

NCT04843761Phase 3Completed

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Role: collaborator

NCT06729593Phase 3Completed

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Role: collaborator